Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1216 daily bars · split adjusted
Current price $0.0576
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 50.67 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 77.01 | Oscillator | Neutral |
| Williams %R (14) | -32.30 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.00 (Hist -0.00) | Oscillator | Sell |
| Average Directional Index (14) | 19.97 (+DI 23.6 / -DI 35.1) | Trend | Neutral |
| EMA 20 | 0.06 | MA | Sell |
| SMA 20 | 0.06 | MA | Sell |
| EMA 50 | 0.05 | MA | Strong Buy |
| SMA 50 | 0.05 | MA | Strong Buy |
| SMA 200 | 0.02 | MA | Strong Buy |
Stock news · updated daily
TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC). The continuing research seeks to evaluate the efficacy and.
TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. Highlights “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive li.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -0.06 | 0.02 | Beat 133.3% | $6.32M |
| May 15, 2026 | -0.06 | -0.05 | Beat 16.7% | $1.98M |
| Mar 30, 2026 | 0.01 | -0.03 | Miss -400.0% | $3.85M |
| Nov 14, 2025 | — | -0.03 | — | $3.38M |
| Aug 14, 2025 | 0.01 | -0.02 | Miss -300.0% | $5.38M |
| May 15, 2025 | — | -0.04 | — | $2.41M |
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 31, 26 | Lee Willis C | director, officer: CEO | P-Purchase | 100,000 @ $0.05 | $5.00K |
| Aug 28, 26 |
| Lee Willis C |
| director, officer: CEO |
| P-Purchase |
| 94,767 @ $0.06 |
| $5.69K |
| Aug 27, 26 | Lee Willis C | director, officer: CEO | P-Purchase | 50,000 @ $0.05 | $2.50K |
| Aug 25, 26 | Lee Willis C | director, officer: CEO | P-Purchase | 46,000 @ $0.04 | $1.84K |
| Aug 29, 25 | Lee Willis C | director, officer: CEO | P-Purchase | 170,000 @ $0.01 | $1.70K |
| May 30, 25 | Lee Willis C | director, officer: CEO | P-Purchase | 70,000 @ $0.02 | $1.40K |
| Apr 16, 26 | Du Henry Huy | director: | 0 | — |
| Oct 1, 24 | Kuwahara Jon | 0 | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | EMMA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.6x | -1.6x · sector 20.7x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | -0.1x | -0.9x | Discount |
| Price / Sales | 0.3x | 1.0x | Discount |
| EV / EBITDA | 9.3x | -28.5x | Discount |
| Return on equity | 9.4% | — | Weak |
| Gross margin | 93.6% | 90.2% | In line |
| Debt / Equity | -0.46 | -0.82 | Conservative |
| Piotroski / Altman Z | 5/9 | Z -26.02 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 2, 2026 | 2026-09-02 15:05:38 | View |
| 8-K | Aug 14, 2026 | 2026-08-14 15:11:19 | View |
| 10-Q | Aug 14, 2026 | 2026-08-14 14:21:35 | View |
| 8-K | May 15, 2026 | 2026-05-15 16:29:39 | View |
| 10-Q | May 15, 2026 | 2026-05-15 15:03:31 | View |
| 3 | Apr 21, 2026 | 2026-04-21 19:11:57 | View |
| 8-K | Apr 17, 2026 | 2026-04-17 17:16:23 | View |
| 8-K | Apr 14, 2026 | 2026-04-14 16:43:18 | View |
| 8-K | Mar 31, 2026 | 2026-03-31 08:00:39 | View |
| 10-K | Mar 31, 2026 | 2026-03-30 21:52:25 | View |
Proxy statement (DEF 14A) disclosures